Protalix BioTherapeutics, Inc. (PLX)
USD 2.26
(-3.63%)
USD 2.26
(-3.63%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 8.31 Million USD | 155.68% |
| 2022 | -14.92 Million USD | 56.08% |
| 2021 | -33.98 Million USD | -128.21% |
| 2020 | -14.89 Million USD | 43.25% |
| 2019 | -26.24 Million USD | 0.81% |
| 2018 | -26.45 Million USD | 68.97% |
| 2017 | -85.27 Million USD | -190.4% |
| 2016 | -29.36 Million USD | -150.6% |
| 2015 | 58.03 Million USD | 293.82% |
| 2014 | -29.94 Million USD | -7.75% |
| 2013 | -27.79 Million USD | -139.2% |
| 2012 | -11.61 Million USD | 68.2% |
| 2011 | -36.52 Million USD | -25.97% |
| 2010 | -28.99 Million USD | 7.77% |
| 2009 | -31.44 Million USD | -40.27% |
| 2008 | -22.41 Million USD | 0.3% |
| 2007 | -22.48 Million USD | -139.41% |
| 2006 | -9.39 Million USD | -12431.53% |
| 2005 | -74.93 Thousand USD | 53.19% |
| 2004 | -160.07 Thousand USD | -13.76% |
| 2003 | -140.71 Thousand USD | 6.04% |
| 2002 | -149.76 Thousand USD | 54.5% |
| 2001 | -329.17 Thousand USD | -211.69% |
| 2000 | -105.6 Thousand USD | 89.42% |
| 1999 | -997.86 Thousand USD | 12.99% |
| 1998 | -1.14 Million USD | -1068.21% |
| 1997 | 118.44 Thousand USD | -10.05% |
| 1996 | 131.68 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.59 Million USD | 23.97% |
| 2024 Q2 | -2.2 Million USD | 52.06% |
| 2023 Q1 | -3.13 Million USD | 16.28% |
| 2023 FY | 8.31 Million USD | 155.68% |
| 2023 Q3 | -1.85 Million USD | -109.58% |
| 2023 Q2 | 19.33 Million USD | 717.66% |
| 2023 Q4 | -6.04 Million USD | -226.35% |
| 2022 Q1 | -2.7 Million USD | 59.47% |
| 2022 Q2 | -5.14 Million USD | -90.38% |
| 2022 Q3 | -4 Million USD | 22.06% |
| 2022 FY | -14.92 Million USD | 56.08% |
| 2022 Q4 | -3.74 Million USD | 6.71% |
| 2021 Q2 | -11.24 Million USD | -105.32% |
| 2021 Q1 | -5.47 Million USD | -1479.09% |
| 2021 Q3 | -4.19 Million USD | 62.65% |
| 2021 FY | -33.98 Million USD | -128.21% |
| 2021 Q4 | -6.66 Million USD | -58.78% |
| 2020 Q4 | 397 Thousand USD | 108.95% |
| 2020 Q1 | 1.66 Million USD | 472.85% |
| 2020 Q2 | -4.15 Million USD | -348.95% |
| 2020 Q3 | -4.43 Million USD | -6.92% |
| 2020 FY | -14.89 Million USD | 43.25% |
| 2019 Q3 | -3.56 Million USD | 54.02% |
| 2019 FY | -26.24 Million USD | 0.81% |
| 2019 Q1 | -7.26 Million USD | -174.27% |
| 2019 Q2 | -7.74 Million USD | -6.59% |
| 2019 Q4 | 291 Thousand USD | 108.17% |
| 2018 Q4 | 9.78 Million USD | 162.92% |
| 2018 Q3 | -15.54 Million USD | -37.63% |
| 2018 Q1 | -9.4 Million USD | 37.92% |
| 2018 FY | -26.45 Million USD | 68.97% |
| 2018 Q2 | -11.29 Million USD | -20.15% |
| 2017 FY | -85.27 Million USD | -190.4% |
| 2017 Q2 | 450 Thousand USD | 100.76% |
| 2017 Q4 | -15.14 Million USD | -32.39% |
| 2017 Q3 | -11.43 Million USD | -2641.56% |
| 2017 Q1 | -59.14 Million USD | -2154.12% |
| 2016 Q1 | -8.59 Million USD | -111.79% |
| 2016 Q3 | -7.29 Million USD | 32.83% |
| 2016 Q2 | -10.85 Million USD | -26.23% |
| 2016 FY | -29.36 Million USD | -150.6% |
| 2016 Q4 | -2.62 Million USD | 64.01% |
| 2015 Q2 | -5.07 Million USD | 15.09% |
| 2015 FY | 58.03 Million USD | 293.82% |
| 2015 Q4 | 72.9 Million USD | 2008.38% |
| 2015 Q3 | -3.82 Million USD | 24.67% |
| 2015 Q1 | -5.97 Million USD | 29.48% |
| 2014 FY | -29.94 Million USD | -7.75% |
| 2014 Q4 | -8.46 Million USD | -5.73% |
| 2014 Q1 | -7.34 Million USD | 32.52% |
| 2014 Q3 | -8.01 Million USD | -30.9% |
| 2014 Q2 | -6.11 Million USD | 16.69% |
| 2013 Q1 | -4.32 Million USD | 56.25% |
| 2013 Q3 | -5.74 Million USD | 15.94% |
| 2013 FY | -27.79 Million USD | -139.2% |
| 2013 Q4 | -10.88 Million USD | -89.4% |
| 2013 Q2 | -6.83 Million USD | -58.23% |
| 2012 FY | -11.61 Million USD | 68.2% |
| 2012 Q4 | -9.87 Million USD | -80.27% |
| 2012 Q3 | -5.47 Million USD | -156.82% |
| 2012 Q1 | -5.9 Million USD | 33.76% |
| 2012 Q2 | 9.64 Million USD | 263.31% |
| 2011 Q3 | -8.87 Million USD | 35.17% |
| 2011 Q2 | -13.68 Million USD | -170.96% |
| 2011 Q1 | -5.05 Million USD | 40.76% |
| 2011 Q4 | -8.91 Million USD | -0.43% |
| 2011 FY | -36.52 Million USD | -25.97% |
| 2010 Q2 | -10.04 Million USD | -26.22% |
| 2010 Q3 | -2.47 Million USD | 75.36% |
| 2010 FY | -28.99 Million USD | 7.77% |
| 2010 Q4 | -8.52 Million USD | -244.7% |
| 2010 Q1 | -7.95 Million USD | 46.74% |
| 2009 Q4 | -14.93 Million USD | -153.41% |
| 2009 Q3 | -5.89 Million USD | -8.61% |
| 2009 Q2 | -5.42 Million USD | -4.71% |
| 2009 FY | -31.44 Million USD | -40.27% |
| 2009 Q1 | -5.18 Million USD | 21.18% |
| 2008 Q2 | -4.22 Million USD | 17.29% |
| 2008 FY | -22.41 Million USD | 0.3% |
| 2008 Q4 | -6.57 Million USD | -1.23% |
| 2008 Q1 | -5.11 Million USD | 0.35% |
| 2008 Q3 | -6.49 Million USD | -53.61% |
| 2007 Q2 | -12.6 Million USD | -265.33% |
| 2007 FY | -22.48 Million USD | -139.41% |
| 2007 Q4 | -5.13 Million USD | -8.11% |
| 2007 Q3 | -4.74 Million USD | 62.35% |
| 2007 Q1 | -3.45 Million USD | 62.91% |
| 2006 Q2 | 28.89 Thousand USD | 356.94% |
| 2006 Q1 | -11.24 Thousand USD | 43.34% |
| 2006 FY | -9.39 Million USD | -12431.53% |
| 2006 Q4 | -9.3 Million USD | -8616.34% |
| 2006 Q3 | -106.7 Thousand USD | -469.25% |
| 2005 FY | -74.93 Thousand USD | 53.19% |
| 2005 Q4 | -19.85 Thousand USD | 37.86% |
| 2005 Q3 | -31.94 Thousand USD | -150.05% |
| 2005 Q2 | -12.77 Thousand USD | -23.34% |
| 2005 Q1 | -10.35 Thousand USD | 67.16% |
| 2004 Q3 | -43.29 Thousand USD | 26.05% |
| 2004 Q1 | -26.69 Thousand USD | 42.21% |
| 2004 Q2 | -58.54 Thousand USD | -119.32% |
| 2004 Q4 | -31.54 Thousand USD | 27.13% |
| 2004 FY | -160.07 Thousand USD | -13.76% |
| 2003 Q1 | -32.48 Thousand USD | 34.59% |
| 2003 FY | -140.71 Thousand USD | 6.04% |
| 2003 Q2 | -29.78 Thousand USD | 8.32% |
| 2003 Q3 | -32.25 Thousand USD | -8.3% |
| 2003 Q4 | -46.18 Thousand USD | -43.19% |
| 2002 Q1 | -35.75 Thousand USD | 36.21% |
| 2002 Q2 | -32.17 Thousand USD | 10.02% |
| 2002 Q4 | -49.67 Thousand USD | -54.46% |
| 2002 Q3 | -32.15 Thousand USD | 0.06% |
| 2002 FY | -149.76 Thousand USD | 54.5% |
| 2001 Q3 | -48.32 Thousand USD | 7.99% |
| 2001 FY | -329.17 Thousand USD | -211.69% |
| 2001 Q2 | -52.52 Thousand USD | 69.51% |
| 2001 Q1 | -172.26 Thousand USD | -166.67% |
| 2001 Q4 | -56.06 Thousand USD | -16.01% |
| 2000 Q3 | 12.42 Thousand USD | 203.12% |
| 2000 FY | -105.6 Thousand USD | 89.42% |
| 2000 Q1 | -41.38 Thousand USD | 89.03% |
| 2000 Q4 | -64.59 Thousand USD | -619.91% |
| 2000 Q2 | -12.04 Thousand USD | 70.89% |
| 1999 Q2 | -37.56 Thousand USD | 89.9% |
| 1999 Q1 | -372.05 Thousand USD | 58.2% |
| 1999 FY | -997.86 Thousand USD | 12.99% |
| 1999 Q4 | -377.28 Thousand USD | -78.85% |
| 1999 Q3 | -210.95 Thousand USD | -461.54% |
| 1998 Q1 | -200 Thousand USD | -5.26% |
| 1998 Q2 | -50 Thousand USD | 75.0% |
| 1998 Q3 | -10 Thousand USD | 80.0% |
| 1998 Q4 | -890 Thousand USD | -8800.0% |
| 1998 FY | -1.14 Million USD | -1068.21% |
| 1997 Q2 | -140 Thousand USD | -40.0% |
| 1997 Q3 | -200 Thousand USD | -42.86% |
| 1997 Q4 | -190 Thousand USD | 5.0% |
| 1997 FY | 118.44 Thousand USD | -10.05% |
| 1997 Q1 | -100 Thousand USD | -225.0% |
| 1996 FY | 131.68 Thousand USD | 0.0% |
| 1996 Q3 | 30 Thousand USD | 0.0% |
| 1996 Q4 | 80 Thousand USD | 166.67% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 128.7% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | 196.293% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 112.039% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 117.027% |
| Azitra, Inc. | -11.28 Million USD | 173.663% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | 208.881% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | 212.617% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 128.45% |
| CEL-SCI Corporation | -32.36 Million USD | 125.681% |
| iBio, Inc. | -24.9 Million USD | 133.372% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | 138.686% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | 142.037% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | 136.23% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 154.767% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | 186.224% |
| NanoViricides, Inc. | -8.29 Million USD | 200.215% |
| Oragenics, Inc. | -20.65 Million USD | 140.241% |
| BiomX Inc. | -26.16 Million USD | 131.763% |
| BiomX Inc. | -26.16 Million USD | 131.763% |
| Palatin Technologies, Inc. | -29.73 Million USD | 127.953% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 118.382% |
| Theriva Biologics, Inc. | -18.34 Million USD | 145.299% |